<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39350571</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1751-2980</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of digestive diseases</Title><ISOAbbreviation>J Dig Dis</ISOAbbreviation></Journal><ArticleTitle>Long-term intermittent oral administration of selective COX-2 inhibitor improved the clinical outcomes of COVID-19 in patients with cirrhosis.</ArticleTitle><Pagination><StartPage>517</StartPage><EndPage>524</EndPage><MedlinePgn>517-524</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1751-2980.13313</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Patients with cirrhosis are more susceptible to coronavirus disease 2019 (COVID-19) due to immune dysfunction. In this retrospective study we aimed to investigate whether suppression of mild systemic inflammation with selective cyclooxygenase-2 inhibitor (COX-2-I) during chronic care of cirrhotic patients would reduce the occurrence of acute decompensated events and improve patient prognosis of COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Medical records of cirrhotic patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were sequentially reviewed. The patients were divided into the COX-2-I and control groups depending on whether they took oral selective COX-2-I for over 3 months or not. The primary outcomes included the occurrence of severe/critical COVID-19, acute decompensated events, and acute-on-chronic liver failure (ACLF).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After propensity score matching analysis, there were 314 cases in the control group and 118 cases in the COX-2-I group. Compared with the control group, the risk of severe/critical COVID-19 in the COX-2-I group was significantly decreased by 83.1% (p = 0.004). Acute decompensated events and ACLF occurred in 23 (7.32%) and nine (2.87%) cases in the control group, but none in the COX-2-I group (p = 0.003 and 0.122). The rate of hospitalization in the COX-2-I group was significantly lower than that of the control group (3.39% vs 13.06%, p = 0.003). No patient in the COX-2-I group required intensive care unit admission.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long-term intermittent oral administration of selective COX-2-I in cirrhotic patients significantly reduces the occurrence of severe/critical COVID-19, acute decompensated events, and ACLF. It may also be used for systemic inflammation caused by other pathogens.</AbstractText><CopyrightInformation>© 2024 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6751-3036</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jing Sun</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jin Hang</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Cheng Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhi Yin</ForeName><Initials>ZY</Initials><Identifier Source="ORCID">0000-0002-8322-1786</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82000613</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>82241054</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>82170625</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>ZYGD23029</GrantID><Agency>135 Projects for Disciplines of Excellence of West China Hospital, Sichuan University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>J Dig Dis</MedlineTA><NlmUniqueID>101302699</NlmUniqueID><ISSNLinking>1751-2972</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052246">Cyclooxygenase 2 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="Y">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052246" MajorTopicYN="Y">Cyclooxygenase 2 Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065290" MajorTopicYN="N">Acute-On-Chronic Liver Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">acute decompensation</Keyword><Keyword MajorTopicYN="N">cyclooxygenase 2 inhibitors</Keyword><Keyword MajorTopicYN="N">liver cirrhosis</Keyword><Keyword MajorTopicYN="N">systemic inflammation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>2</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39350571</ArticleId><ArticleId IdType="doi">10.1111/1751-2980.13313</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Marjot T, Eberhardt CS, Boettler T, et al. Impact of COVID‐19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper. J Hepatol. 2022;77(4):1161‐1197.</Citation></Reference><Reference><Citation>Ioannou GN, Liang PS, Locke E, et al. Cirrhosis and severe acute respiratory syndrome coronavirus 2 infection in US veterans: risk of infection, hospitalization, ventilation, and mortality. Hepatology. 2021;74(1):322‐335.</Citation></Reference><Reference><Citation>Jalan R, D'Amico G, Trebicka J, Moreau R, Angeli P, Arroyo V. New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. J Hepatol. 2021;75(Suppl 1):S14‐S26.</Citation></Reference><Reference><Citation>Gao JH, Wen SL, Feng S, et al. Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats. Angiogenesis. 2016;19(4):501‐511.</Citation></Reference><Reference><Citation>Gao JH, Wen SL, Tong H, et al. Inhibition of cyclooxygenase‐2 alleviates liver cirrhosis via improvement of the dysfunctional gut‐liver axis in rats. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G962‐G972.</Citation></Reference><Reference><Citation>Huang ZY, Ma X, Jia XT, et al. Prevention of severe acute pancreatitis with cyclooxygenase‐2 inhibitors: a randomized controlled clinical trial. Am J Gastroenterol. 2020;115(3):473‐480.</Citation></Reference><Reference><Citation>Mallet V, Beeker N, Bouam S, Sogni P, Pol S. Prognosis of French COVID‐19 patients with chronic liver disease: a national retrospective cohort study for 2020. J Hepatol. 2021;75(4):848‐855.</Citation></Reference><Reference><Citation>Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology. 2020;159(2):768‐771.e3.</Citation></Reference><Reference><Citation>Ge J, Pletcher MJ, Lai JC. Outcomes of SARS‐CoV‐2 infection in patients with chronic liver disease and cirrhosis: a national COVID Cohort Collaborative Study. Gastroenterology. 2021;161(5):1487‐1501.e5.</Citation></Reference><Reference><Citation>Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS‐CoV‐2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74(3):567‐577.</Citation></Reference><Reference><Citation>Wang M, Liu ZD, Wang ZL, et al. Clinical characteristics of 1139 mild cases of the SARS‐CoV‐2 omicron variant infected patients in Shanghai. J Med Virol. 2023;95(1):e28224. doi:10.1002/jmv.28224</Citation></Reference><Reference><Citation>Chaimayo C, Kaewnaphan B, Tanlieng N, et al. Rapid SARS‐CoV‐2 antigen detection assay in comparison with real‐time RT‐PCR assay for laboratory diagnosis of COVID‐19 in Thailand. Virol J. 2020;17(1):177. doi:10.1186/s12985‐020‐01452‐5</Citation></Reference><Reference><Citation>Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point‐of‐care antigen and molecular‐based tests for diagnosis of SARS‐CoV‐2 infection. Cochrane Database Syst Rev. 2021;3(3):CD013705. doi:10.1002/14651858.CD013705.pub2</Citation></Reference><Reference><Citation>World Health Organization. Living guidance for clinical management of COVID‐19. Available from: https://iris.who.int/bitstream/handle/10665/349321/WHO-2019-nCoV-clinical-2021.2-eng.pdf?sequence=1</Citation></Reference><Reference><Citation>Arroyo V, Moreau R, Jalan R, Ginès P. Acute‐on‐chronic liver failure: a new syndrome that will re‐classify cirrhosis. J Hepatol. 2015;62(1 Suppl):S131‐S143.</Citation></Reference><Reference><Citation>Hernaez R, Solà E, Moreau R, Ginès P. Acute‐on‐chronic liver failure: an update. Gut. 2017;66(3):541‐553.</Citation></Reference><Reference><Citation>Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15):1448‐1455.</Citation></Reference><Reference><Citation>Romanovsky AA, Almeida MC, Aronoff DM, et al. Fever and hypothermia in systemic inflammation: recent discoveries and revisions. Front Biosci. 2005;10:2193‐2216.</Citation></Reference><Reference><Citation>European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397‐417.</Citation></Reference><Reference><Citation>Garcia‐Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104(7):1802‐1829.</Citation></Reference><Reference><Citation>de Franchis R, Bosch J, Garcia‐Tsao G, Reiberger T, Ripoll C. Baveno VII ‐ renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959‐974.</Citation></Reference><Reference><Citation>Khan MU, Mushtaq K, Alkaabi SR. Acute‐on‐chronic liver failure: possibly the main culprit of increased mortality in COVID‐19 patients with liver disease. Gastroenterology. 2021;160(5):1894‐1895.</Citation></Reference><Reference><Citation>Li PH, Liu Y, Cheng ZQ, Yu XR, Li YX. COVID‐19‐associated liver injury: clinical characteristics, pathophysiological mechanisms and treatment management. Biomed Pharmacother. 2022;154:113568. doi:10.1016/j.biopha.2022.113568</Citation></Reference><Reference><Citation>Ji D, Zhang DW, Yang TN, et al. Effect of COVID‐19 on patients with compensated chronic liver diseases. Hepatol Int. 2020;14(5):701‐710.</Citation></Reference><Reference><Citation>Tai Y, Zhao C, Zhang LH, et al. Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress. J Cell Mol Med. 2021;25(22):10389‐10402.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>